INTRODUCTION
============

Since its first introduction into clinical practice in 1993,[@B1] transradial approach has been increasingly adopted for percutaneous coronary intervention (PCI) over the past two decades. Comparing with traditional transfemoral intervention (TFI), transradial intervention (TRI) has been shown to hold potential advantages of fewer access site-related bleeding and vascular complications and better patients\' satisfaction.[@B2][@B3][@B4][@B5][@B6][@B7][@B8] So far the safety and efficacy of TRI has been demonstrated in several specific patient populations, such as the elderly and the obesity.[@B9][@B10][@B11]

Due to their high prevalence of coronary artery disease (CAD), women represent another large group of patients who will possibly benefit from PCI.[@B12][@B13] However, they are often under-represented in clinical studies.[@B14][@B15] Therefore, the role of TRI in women remains to be further defined. Using data from the Fuwai database, a single-center registry based on the largest heart center in People\'s Republic of China, we sought to examine the safety and efficacy of TRI in women in China.

METHODS
=======

Study population
----------------

Our study population consisted of 5,067 women undergoing PCI at Fuwai Hospital, Beijing, China between 2006 and 2011. TRI was performed in 4,105 patients and 962 patients received TFI. Patients were prospectively followed up for around 1 year after discharge. The Institutional Review Board of Fuwai Hospital, Peking Union Medical College (approval number: 2016-847), approved the study and waived the requirement for informed consent.

Endpoint definition
-------------------

The primary endpoint was major adverse cardiac events (MACEs) during hospitalization and at 1-year follow-up. It is a composite of cardiac death, myocardial infarction (MI), and target vessel revascularization (TVR). Secondary endpoints included each component of the primary endpoint, major bleeding, and access site complications.

Bleeding events were evaluated according to the Bleeding Academic Research Consortium (BARC) definition[@B16] and major bleeding was defined as a bleeding event with BARC grade ≥3. Access site complications in our study included local hematoma that prolonged hospital stay, mediastinal hematoma, retroperitoneal hematoma, aneurysm, and arteriovenous fistula. Patients\' baseline and procedural characteristics were obtained from medical record system and the catheterization laboratory\'s database. In-hospital outcomes were validated by medical record review. Follow-up was performed by trained staff at Fuwai Hospital via phone visits at 6 months and 1 year after discharge.

Statistical analysis
--------------------

Continuous variables were expressed as mean±standard deviation and compared using Student\'s t-test. Categorical variables were described using frequencies and percentages and compared using chi-square test or Fisher\'s exact test, as appropriate. In-hospital and 1-year outcomes between TRI and TFI groups were analyzed by logistic and Cox regression respectively and were expressed as odds ratio (OR)/hazard ratio (HR) and 95% confidence interval (CI).

Since treatment decisions (TRI or TFI) in real-world practice is not made based on randomization, a 1:1 matched propensity score matching (PSM) was performed to control for potential biases. Propensity scores were calculated from a logistic regression model with access route as the dependent variable. Independent variables included age; prior history of MI, coronary artery bypass grafting (CABG) surgery, PCI, stroke, diabetes mellitus (DM), hypertension, or hyperlipidemia; clinical diagnosis; left ventricle ejection fraction (LVEF) before PCI; hemoglobin level before PCI; creatinine concentration before PCI; use of glycoprotein (GP) IIb/IIIa inhibitors; use of low molecular weight heparin; single-, double-,or triple-vessel lesion; left main disease; lesion type (de novo, intrastent, or restenosis); lesion location (ostial or bifurcation lesion); chronic total occlusion; number of treated lesion; number of stents used; use of drug-eluting stents (DESs). The caliper was set as 0.02. In the end 899 pairs were matched and the C-statistics for the propensity score model was 0.63. Paired t-test for continuous variables and paired χ^2^ test or Fisher exact test for categorical variables were then performed within the matched patients. Data were analyzed according to intention-to-treat principle (before the potential crossover). All statistical analyses were performed using IBM SPSS Software, version 22.0 (IBM Corp., Armonk, NY, USA) and a 2-sided p\<0.05 was considered significant.

RESULTS
=======

Baseline and procedural characteristics of women undergoing TRI and TFI are shown in [Tables 1](#T1){ref-type="table"} and [2](#T2){ref-type="table"}. Compared with TFI, TRI patients were slightly younger; had lower prevalence of prior MI, CABG, or PCI; higher prevalence of DM; less likely to present with ST-segment elevated MI; and were more likely to have stable angina. They were also more likely to undergo PCI for single or double-vessel lesions and were less likely to receive the procedure for triple-vessel lesions, left main diseases, or ostial lesions. TRI group were also noted to have a shorter average total procedure time. After PSM, all characteristics were well-balanced between TRI and TFI patients.

###### Baseline characteristics of women undergoing TRI and TFI

![](kcj-48-719-i001)

  Characteristics             All patients      Propensity score-matched patients                                                       
  --------------------------- ----------------- ----------------------------------- ------------ ------------ ------------ ------------ -------
  Age (year)                  62.6±8.9          64.4±9.4                            \<0.001      63.5±9.1     64.2±9.4     0.150        
  Medical history                                                                                                                       
                              MI                620 (15.1)                          215 (22.3)   \<0.001      192 (21.4)   198 (22.0)   0.731
                              Prior CABG        34 (0.8)                            87 (9.0)     \<0.001      34 (3.8)     38 (4.2)     0.630
                              Prior PCI         483 (11.8)                          174 (18.1)   \<0.001      142 (15.8)   151 (16.8)   0.565
                              Stroke            204 (5.0)                           61 (6.3)     0.085        64 (7.1)     57 (6.3)     0.510
                              DM                1,226 (29.9)                        244 (25.4)   0.006        255 (28.4)   224 (24.9)   0.098
                              Hypertension      2,770 (67.5)                        661 (68.7)   0.462        623 (69.3)   613 (68.2)   0.611
                              Hyperlipidemia    2,204 (53.7)                        498 (51.8)   0.282        471 (52.4)   464 (51.6)   0.741
  Diagnosis                                                                                                                             
                              STEMI             463 (11.3)                          132 (13.7)   0.034        134 (14.9)   124 (13.8)   0.501
                              NSTEMI            253 (6.2)                           62 (6.4)     0.745        61 (6.8)     60 (6.7)     0.925
                              Unstable angina   2,045 (49.8)                        504 (52.4)   0.151        447 (49.7)   468 (52.1)   0.322
                              Stable angina     1,223 (29.8)                        238 (24.7)   0.002        231 (25.7)   223 (24.8)   0.664
                              Others            120 (2.9)                           26 (2.7)     0.713        26 (2.9)     24 (2.7)     0.774
  LVEF (%)                    62.7±7.4          61.7±7.8                            \<0.001      62.1±7.4     61.7±7.9     0.240        
  LVEF (\<50%)                80 (1.9)          27 (1.8)                            0.096        18 (2.0)     25 (2.8)     0.280        
  Hemoglobin (g/L)            124.8±11.4        123.9±13.2                          0.048        124.1±11.9   123.8±13.4   0.609        
  Creatinine (µmol/L)         67.3±15.2         69.5±16.5                           \<0.001      67.7±15.9    69.2±16.2    0.053        
  GP IIb/IIIa usage           89 (2.2)          32 (3.3)                            0.034        22 (2.4)     28 (3.1)     0.389        
  LMWH usage                  3,136 (76.4)      660 (68.6)                          \<0.001      640 (71.2)   616 (68.5)   0.217        
  Fondaparinux sodium usage   29 (0.7)          8 (0.8)                             0.682        5 (0.6)      7 (0.8)      0.772        

Dara shown are number (%) or mean±SD.

CABG = coronary arterial bypass grafting; DM = diabetes mellitus; GP = glycoprotein; LMWH = low molecular weight heparin; LVEF = left ventricle ejection fraction; MI = myocardial infarction; NSTEMI = non-ST-segment elevation myocardial infarction; PCI = percutaneous coronary intervention; TFI = transfemoral intervention; TRI = transradial intervention; SD = standard deviation; STEMI, ST-segment elevation myocardial infarction.

###### Angiographic and procedural characteristics of women undergoing TRI and TFI
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  Characteristics                All patients         Propensity score-matched patients                                                       
  ------------------------------ -------------------- ----------------------------------- ------------ ------------ ------------ ------------ -------
  Left main disease              234 (5.7)            142 (14.8)                          \<0.001      112 (12.5)   111 (12.3)   0.943        
  Diseased coronary vessels                                                                                                                   
                                 Single vessel        1,253 (30.5)                        259 (26.9)   0.028        239 (26.6)   257 (28.6)   0.342
                                 Double vessel        1,263 (30.8)                        248 (25.8)   0.002        267 (29.7)   240 (26.7)   0.157
                                 Triple vessel        1,559 (38.0)                        440 (45.7)   \<0.001      374 (41.6)   389 (43.3)   0.474
  Lesion type                                                                                                                                 
                                 De novo              4,025 (98.1)                        922 (95.8)   \<0.001      878 (97.7)   869 (96.7)   0.201
                                 Intra stent          66 (1.6)                            30 (3.1)     \<0.001      16 (1.8)     24 (2.7)     0.201
                                 Restenosis           14 (0.3)                            10 (1.0)     0.009        5 (0.6)      6 (0.7)      0.762
  Lesion location                                                                                                                             
                                 Ostial lesion        436 (10.6)                          163 (16.9)   \<0.001      118 (13.1)   147 (16.4)   0.054
                                 Bifurcation lesion   1,406 (34.3)                        345 (35.9)   0.344        306 (34.0)   323 (35.9)   0.401
  Chronic total occlusion        346 (8.4)            104 (10.8)                          0.019        80 (8.9)     101 (11.2)   0.100        
  Number of treated lesion       1.5±0.7              1.5±0.7                             0.181        1.4±0.7      1.5±0.7      0.090        
  Number of stents used          1.9±1.0              1.9±1.1                             0.124        1.9±1.0      1.9±1.0      0.316        
  DES usage                      4,083 (99.5)         935 (97.2)                          \<0.001      894 (99.4)   887 (98.7)   0.088        
  Intravascular ultrasound       102 (2.5)            61 (6.3)                            \<0.001      44 (4.9)     57 (6.3)     0.183        
  IABP support                   43 (1.0)             19 (2.0)                            0.019        19 (2.1)     19 (2.1)     1            
  Total procedure time, minute   38.1±26.2            42.6±26.5                           \<0.001      39.6±21.6    41.5±24.2    0.069        
  Contrast volume (mL)           149.3±71.6           157.9±84.6                          0.004        149.7±71.9   154.1±82.0   0.221        
  Dissection                     39 (1.0)             12 (1.2)                            0.406        16 (1.8)     12 (1.3)     0.446        
  Acute thrombosis               8 (0.2)              6 (0.6)                             0.052        4 (0.4)      6 (0.7)      0.526        

Dara shown are number (%) or mean±SD.

DES = drug-eluting stent; IABP = intra-aortic balloon pump; TFI = transfemoral intervention; TRI = transradial intervention; SD = standard deviation.

Sixty-nine patients (1.7%) had failed TRI procedure and were converted to TFI. No patients in the TFI group were crossed over to the TRI group. A vascular closure device was used in 388 (40.3%) patients in the TFI group.

Bleeding and complications from PCI are shown in [Table 3](#T3){ref-type="table"}. The incidence rates for BARC ≥2 (8.5% vs. 18.7%, p\<0.001) and BARC ≥3 (0.9% vs. 3.2%, p\<0.001) post-PCI bleeding were significantly lower in the TRI group than the TFI group. Both access-site-related (0.6% vs. 2.1%, p\<0.001) and non-access-site-related (0.3% vs. 1.1%, p=0.002) major bleeding were less frequently observed among TRI patients. Moreover, TRI group had significantly fewer access site complications (8.9% vs. 19.5%, p\<0.001), which was mainly due to a lower rate of local hematoma that prolonged hospitalization (8.7% vs. 18.5%, p\<0.001). In propensity score-matched patients, all these differences remained significant (BARC ≥2: 8.5% vs. 18.7%, p\<0.001; BARC ≥3: 1.0% vs. 3.4%, p\<0.001; and access site complications: 8.8% vs. 19.9%, p\<0.001, respectively) ([Figure 1](#F1){ref-type="fig"}).

###### Bleeding and complications of women undergoing TRI and TFI
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  Complications                            All patients   Propensity score-matched patients                                     
  ---------------------------------------- -------------- ----------------------------------- --------- ---------- ------------ ---------
  BARC ≥2 bleeding                         350 (8.5)      180 (18.7)                          \<0.001   76 (8.5)   168 (18.7)   \<0.001
  BARC ≥3 bleeding                         36 (0.9)       31 (3.2)                            \<0.001   9 (1.0)    31 (3.4)     \<0.001
  Access-site-related major bleeding       23 (0.6)       20 (2.1)                            \<0.001   6 (0.7)    20 (2.2)     0.006
  Non-access-site-related major bleeding   13 (0.3)       11 (1.1)                            0.002     3 (0.3)    11 (1.2)     0.032
  Access site complications                364 (8.9)      188 (19.5)                          \<0.001   79 (8.8)   179 (19.9)   \<0.001
  Local hematoma                           357 (8.7)      178 (18.5)                          \<0.001   77 (8.6)   169 (18.8)   \<0.001
  Mediastinal hematoma                     1 (0)          2 (0.2)                             0.094     0          2 (0.2)      0.500
  Retroperitoneal hematoma                 1 (0)          2 (0.2)                             0.094     0          2 (0.2)      0.500
  Aneurysm                                 4 (0.1)        3 (0.3)                             0.131     1 (0.1)    3 (0.3)      0.625
  Arteriovenous fistula                    1 (0)          3 (0.3)                             0.023     1 (0.1)    3 (0.3)      0.625
  Transfusion                              3 (0.1)        6 (0.6)                             0.002     1 (0.1)    6 (0.7)      0.124

Dara shown are number (%).

BARC = Bleeding Academic Research Consortium; TFI = transfemoral intervention; TRI = transradial intervention.

![Comparison of bleeding and access site complication between TRI and TFI groups in propensity score-matched patients.\
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In-hospital outcomes are shown in [Table 4](#T4){ref-type="table"}. The rates of MACE, MI, and TVR were similar in the 2 groups both before and after PSM. Cardiac death was less frequently observed among TRI patients (0.1% vs. 0.5%, p=0.016) but this did not remain significant in propensity score-matched patients. Logistic regression analysis showed that TRI was an independent predictor of reduced in-hospital major bleeding (OR, 0.64; 95% CI, 0.54--0.76; p\<0.001) and access site complications (OR, 0.67; 95% CI, 0.61--0.74; p\<0.001).

###### In-hospital and 1-year outcomes of women undergoing TRI and TFI
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  Outcomes               All patients                Propensity score-matched patients                                                                                          
  ---------------------- --------------------------- ----------------------------------- ------------ ------------------- --------- ---------- ------------ ------------------- ---------
  In-hospital outcomes                                                                                                                                                          
                         MACE                        65 (1.6)                            21 (2.2)     0.77 (0.53--1.13)   0.195     15 (1.7)   20 (2.2)     0.87 (0.65--1.17)   0.393
                         Cardiac death               4 (0.1)                             5 (0.5)      0.34 (0.19--0.61)   0.016     2 (0.2)    5 (0.6)      0.70 (0.44--1.12)   0.452
                         MI                          61 (1.5)                            17 (1.8)     0.87 (0.57--1.33)   0.524     13 (1.4)   16 (1.8)     0.91 (0.65--1.26)   0.574
                         TVR                         4 (0.1)                             2 (0.2)      0.57 (0.18--1.77)   0.320     1 (0.1)    2 (0.2)      0.75 (0.34--1.67)   1
                         Major bleeding              36 (0.9)                            31 (3.2)     0.40 (0.31--0.52)   \<0.001   9 (1.0)    31 (3.5)     0.64 (0.54--0.76)   \<0.001
                         Access site complications   364 (8.9)                           188 (19.5)   0.50 (0.44--0.58)   \<0.001   79 (8.8)   179 (19.9)   0.67 (0.61--0.74)   \<0.001
  One-year outcomes                                                                                                                                                             
                         MACE                        100 (2.4)                           32 (3.3)     0.78 (0.57--1.06)   0.119     24 (2.7)   30 (3.3)     0.90 (0.70--1.14)   0.407
                         Cardiac death               13 (0.3)                            6 (0.6)      0.60 (0.31--1.17)   0.234     4 (0.4)    6 (0.7)      0.83 (0.50--1.38)   0.526
                         MI                          7 (0.2)                             3 (0.3)      0.63 (0.25--1.63)   0.413     1 (0.1)    3 (0.3)      0.67 (0.38--1.18)   0.317
                         TVR                         84 (2.0)                            24 (2.5)     0.85 (0.60--1.22)   0.386     21 (2.3)   22 (2.4)     0.98 (0.73--1.31)   0.877

Data shown are number (%) not otherwise specified.

CI = confidence interval; HR = hazard ratio; MACE = major adverse cardiac event; MI = myocardial infarction; OR = odds ratio; TFI = transfemoral intervention; TRI = transradial intervention; TVR = target vessel revascularization.

Follow-up work was completed in all patients with a median follow-up time of 361 days (interquartile range \[IQR\], 354--366 days) and 360 days (IQR, 354--366 days) in TRI and TFI groups respectively. The Kaplan-Meier curves for 1-year outcomes in propensity score-matched patients are shown in [Figure 2](#F2){ref-type="fig"}. Incidence rates of 1-year MACE and its components tended to be lower in TRI group, but this did not reach statistical significance (p\>0.05; [Table 4](#T4){ref-type="table"}).

![Kaplan-Meier curves for occurrence of MACE (A), cardiac death (B), MI (C), and TVR (D) between TRI and TFI groups of 1-year follow-up in propensity score-matched patients.\
MACE = major adverse cardiac event; MI = myocardial infarction; TFI = transfemoral intervention; TRI = transradial intervention; TVR = target vessel revascularization.](kcj-48-719-g002){#F2}

DISCUSSION
==========

The present study represents a large cohort of women undergoing PCI in real world clinical practice. We found that TRI was associated with significantly reduced in-hospital major bleeding and access site complications. Although TRI was more likely to be performed in patients with lower risk, such significance persisted after controlling for potential biases using PSM. Our findings demonstrate the safety and efficacy of TRI in women and add evidence to promote more widespread adoption of TRI in female patients.

Transradial approach has become the primary approach for PCI in China.[@B17] Due to advantages in safety, efficacy, and patients\' satisfaction, it has been widely adopted in clinical practice.[@B2][@B3][@B4][@B5][@B6][@B7][@B8] However, most of the evidences came from studies conducted in both genders, in which women are often under-represented.[@B14][@B15] As for women themselves, they are at higher risk of adverse events after CADs and PCI.[@B13] Performing TRI in women is considered more technically demanding because of smaller caliber radial arteries than men and increased rate of vasospasms, which could lead to procedure failure and worse outcomes.[@B18] Thus, it is reasonable to believe that women may respond to treatment strategies differently than men, and the safety and efficacy of TRI in women should be evaluated separately. However, only a few studies have compared TRI with TFI in female patients so far.[@B18][@B19][@B20][@B21]

Bleeding has been recognized as a strong predictor of worst outcomes after PCI.[@B22] Several bleeding avoidance strategies have been suggested to improve safety of the procedure, including pharmacological, technological, and procedural approaches.[@B23] As one of the major procedural approaches, TRI has been shown to reduce bleeding by both randomized[@B3][@B5][@B6] and observational[@B8][@B19][@B24][@B25] studies. Since radial arteries are superficial and readily compressible, TRI is also believed to reduce bleeding in women.[@B26] The Radial Vs femorAL access for coronary intervention (RIVAL) trial is the largest randomized TRI versus TFI study up to date.[@B3] Results of its subgroup analysis of women demonstrated that radial access was effective in reducing bleeding complications.^18^ The Study of Access Site for Enhancement of PCI (SAFE-PCI) for Women trial[@B21] represents the first randomized trial of TRI versus TFI performed solely in women. Although the trial was terminated early due to lower than expected rates of endpoint events, there was still a trend of fewer bleeding in women undergoing TRI. Other observational retrospective analyses also came up with similar results, suggesting that women undergoing TRI was less likely to suffer from major BARC bleeding events.[@B19][@B20] Consistent with previous studies, we found that TRI was associated with reduced major post-PCI bleeding (OR, 0.64; 95% CI, 0.54--0.76; p\<0.001). Our findings support the safety of TRI and suggest that its wider adoption could lead to improved outcomes in women.

Lower risk of access site complications is considered another major benefit of TRI.[@B4] However, as stated above, most of the studies supporting this idea were conducted in whole populations, a large proportion of which were men. Previous analyses have shown that the rates of access site vascular complications were higher in women than in men.[@B3][@B18] Randomized studies, including the SAFE-PCI trial and gender-specific sub-analysis of the RIVAL trial, suggested that safety of catheterization was improved by transradial approach in women, with significantly fewer access site vascular complications.[@B18][@B21] As for observational data, the retrospective study by Kedev et al.[@B20] also reported that TRI was associated with less vascular complications than traditional TFI. Our study demonstrated that TRI group had significantly fewer access site complications both before and after PSM adjustments (all patients: 8.9% vs. 19.5%, p\<0.001; propensity score-matched patients: 8.8% vs. 19.9%, p\<0.001). Transradial approach was also identified as an independent predictor of reduced access site complications (OR, 0.67; 95% CI, 0.61--0.74; p\<0.001). Thus, TRI seems to be effective in reducing access site complications in women.

Several limitations of this study should also be acknowledged. First of all, it was a retrospective observational analysis, which was limited by its nonrandomized nature. Although a 1:1 matched PSM was performed to control for potential biases, this was still not an acceptable substitute for randomization. Second, since our study was based on retrospective data, it is possible that the incidence rates of events were underestimated. This could explain the low rate of MACE in our study. Third, the potential advantages of TRI in women are likely to depend on operator\'s experience.[@B27] Researchers from both the RIVAL trial and SAFE-PCI trial have suggested that TRI was shown to be superior to TFI only if performed by experienced operators and therefore its advantages might not be applicable to those who are novice in transradial approach.[@B3][@B18][@B21] Moreover, our study only include data from a single center where TRI dominates. Importantly, operators\' experience and training with transradial approach may differ from site to site. Thus, the generalizability of our findings to other less-experienced centers remains to be further defined.

In conclusion, in this large propensity score-based single center comparison of TRI versus TFI in women, TRI showed advantages of safety and feasibility over TFI, with significant reduction in major post-PCI bleeding and access site complications. A widespread adoption of TRI in women has the potential to improve outcomes in treatment of CADs.
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